MedTrace Logo

MSC for Treatment of CMV Infection

NCT02083731 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-01-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Conditions

  • Stem Cell Transplantation, Hematopoietic
  • CMV Infection
  • Hematological Diseases

Interventions

BIOLOGICAL

MSCs

Sponsors & Collaborators

  • Academy Military Medical Science, China

    collaborator INDUSTRY

  • Peking University People's Hospital

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • Guangzhou General Hospital of Guangzhou Military Command

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Qifa Liu, MD. · Nanfang Hospital, Southern Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-01-31
Completion
2017-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083731 on ClinicalTrials.gov